Landmark trials have shown that GLP-1 receptor agonists, originally developed for diabetes and weight loss, also provide ...

Semaglutide has surged in popularity over the past two years, thanks to its remarkable effectiveness as a long-acting GLP-1 ...

MASH clinical trials test treatments for metabolic dysfunction-associated steatohepatitis, focusing on reversing liver inflammation, fibrosis, and fat accumulation safely. ... Semaglutide. You ...

Semaglutide, the active ingredient in the weight loss drugs Wegovy and Ozempic, ... In a trial involving 800 participants diagnosed with MASH and moderate to severe liver fibrosis, ...

Novo Nordisk sees 65% obesity drug sales growth, forecasts $8.14–$9.59B FY25 free cash flow. Click here to read an analysis ...

Semaglutide is not approved for the treatment of adults with MASH. Safety and efficacy are not established, and there is no guarantee that semaglutide will become commercially available for this ...

Novo Nordisk (NVO) announced the headline results from part 1 of the ongoing ESSENCE trial, a pivotal phase 3, 240-week, double-blinded trial in 1,200 adults with metabolic dysfunction-associated ...

Semaglutide effectively treats liver disease in two thirds of patients, new research has found. ... had shown using semaglutide as a treatment for MASH would have benefit for these patients.

A weekly dose of semaglutide, a drug used to manage diabetes and weight loss, was effective in 63% of patients at treating a serious form of fatty liver disease, a new study has found.

Results of part 1 of the ESSENCE phase 3 trial, published in The New England Journal of Medicine, demonstrated that a greater proportion of patients with MASH achieved resolution of ...